A new tool to enhance the efficacy of chemoembolization to treat primary and metastatic hepatic tumors.

This editorial focuses primarily on a paper that presented the clinical applications of a new material, named DC Bead embolic drug-eluting bead (DEB), which is used to modulate the blood flow in conjunction with chemotherapy in primary and metastatic hepatic tumors. DEB appears to have several advantages over alternative embolization agents, not least of which is its effective capacity of drug diffusion in tumors, thereby making it suitable for ideal treatments.